Adverse effects of antimalarial prophylactic drugs: An important consideration in the risk-benefit equation

Annals of Pharmacotherapy

Volumn 32, Issue 10, 1998, Pages 1104-1106

  Davis, Timothy M E ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CHLOROQUINE; DAPSONE; DOXYCYCLINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE;

ALOPECIA; BLOOD TOXICITY; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; DRUG SAFETY; FETOTOXICITY; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INFECTION PREVENTION; LIVER TOXICITY; MALARIA; MEGALOBLASTIC ANEMIA; NAUSEA; NOTE; PRIORITY JOURNAL; PRURITUS; RETINOPATHY; VERTIGO;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ATOVAQUONE; AZITHROMYCIN; CHLOROGUANIDE; CHLOROQUINE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; MEFLOQUINE; NAPHTHOQUINONES; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIMAQUINE; PYRIMETHAMINE; RISK ASSESSMENT;

EID: 0031738411     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18239     Document Type: Note

References (13)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease study. Lancet 1997;349:1436-42.
2. Hien TT, White NJ. Qinghaosu. Lancet 1993;341:603-8.
3. Centers for Disease Control and Prevention. Specific recommendations for vaccinations and prophylaxis. Malaria. In: Health information for international travel 1996-97. Atlanta: US Department of Health and Human Services, 1997:128-36.
4. Bradley DJ, Warhurst DC. Guidelines for the prevention of malaria in travellers from the United Kingdom. Commun Dis Rep CDR Rev 1997;7:R137-52.
5. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998;351:709-13.
6. Fryauff DJ, Baird JK, Basri H, Sumawinta I, Pumomo, Richie TL, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995;346:1190-3.
7. Andersen SL, Oloo AJ, Ragama OB, Aleman GM, Berman JD, Tang DB, et al. Successful double-blind randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in Western Kenya. Clin Infect Dis 1998;26:146-50.
8. Steffen R. Travel medicine - prevention based on epidemiological data. Trans R Soc Trop Med Hyg 1991;85:156-62.
9. Oostweegel LMM, Beijnen JH, Mulder JW. Hepatitis during chloroguanide prophylaxis. Ann Pharmacother 1998;32:1023-5.
10. Croft AMJ, Garner P. Mefloquine to prevent malaria in non-immune adults. Cochrane Library 1997;3:1-14.
11. Nosten F, ter Kuile FO, Luxemberger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993;341:1054-6.
12. Davis TME, Dembo LG, Kaye-Eddie SA, Hewitt BJ, Hislop RG, Batty KT. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996;43:415-21.
13. Handysides SE. Rise infalciparum malaria imported from east Africa. Eurosurveillance Wkly 1998;(14 May):2-3.